A
Power Law company profile
Apellis Pharmaceuticals
Biotech & Life Sciences · Waltham, United States · Founded 2008 · IPO 2017 Unicorn
Valuation
$5.25B
Market cap · Apr/2026
Revenue
$689M
Latest reported FY
Global footprint
Where Apellis Pharmaceuticals has talent and traffic
Web traffic by country
29K
monthly visits
across markets
across markets
🇺🇸 United States67.9%
🇮🇳 India10%
🇬🇧 United Kingdom7.6%
🇨🇦 Canada4.5%
🇭🇰 Hong Kong3.8%
Patent intelligence
$44M patent portfolio · 30 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$44M
0.84% of market cap · 45.7× smaller than top peer Ablynx ($2B)
30 active patent families
Where Apellis Pharmaceuticals innovates
Complement inhibitorPharmacologyMolecular biologyCell biologyComplement inhibition
Below peer median on Legal, Strategic, Economic, Technology
Quality vs same-sector peers
Apellis Pharmaceuticals on the five Patsnap quality dimensions
Apellis Pharmaceuticals in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Apellis Pharmaceuticals concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Apellis Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Apellis Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.